Literature DB >> 17683277

Microtubule inhibitors as a potential treatment for malaria.

Barbara Kappes1, Petra Rohrbach.   

Abstract

The spread of parasitic resistance has necessitated the development of new drugs and drug targets for the treatment of malaria. Microtubules, which have gained outstanding importance as target molecules for the development of anticancer drugs, are likely to be potent antimalarial targets. The clinical implementation of microtubule inhibitors has given rise to a detailed mechanistic understanding of their interaction with tubulin on the molecular level and their effects on the cellular level. By comparison, our knowledge on Plasmodium falciparum, the causative agent of the most severe form of malaria, is rather poor. This article gives an overview on the microtubule inhibitors that have been explored in the parasite, reviews their effects on parasite growth and assesses their potential as novel antimalarials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17683277     DOI: 10.2217/17460913.2.4.409

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  10 in total

1.  Heterogeneity in the sensitivity of microtubules of Giardia lamblia to the herbicide oryzalin.

Authors:  Letícia L Terra; Loraine Campanati; Wanderley De Souza
Journal:  Parasitol Res       Date:  2010-04-20       Impact factor: 2.289

2.  Small molecule screen for candidate antimalarials targeting Plasmodium Kinesin-5.

Authors:  Liqiong Liu; Jessica Richard; Sunyoung Kim; Edward J Wojcik
Journal:  J Biol Chem       Date:  2014-04-15       Impact factor: 5.157

3.  Rationale for the coadministration of albendazole and ivermectin to humans for malaria parasite transmission control.

Authors:  Kevin C Kobylinski; Haoues Alout; Brian D Foy; Archie Clements; Poom Adisakwattana; Brett E Swierczewski; Jason H Richardson
Journal:  Am J Trop Med Hyg       Date:  2014-07-28       Impact factor: 2.345

4.  MTrack: Automated Detection, Tracking, and Analysis of Dynamic Microtubules.

Authors:  Varun Kapoor; William G Hirst; Christoph Hentschel; Stephan Preibisch; Simone Reber
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

5.  Microtubule number and length determine cellular shape and function in Plasmodium.

Authors:  Benjamin Spreng; Hannah Fleckenstein; Patrick Kübler; Claudia Di Biagio; Madlen Benz; Pintu Patra; Ulrich S Schwarz; Marek Cyrklaff; Friedrich Frischknecht
Journal:  EMBO J       Date:  2019-05-24       Impact factor: 11.598

6.  Interaction of Plasmodium falciparum apicortin with α- and β-tubulin is critical for parasite growth and survival.

Authors:  Malabika Chakrabarti; Nishant Joshi; Geeta Kumari; Preeti Singh; Rumaisha Shoaib; Akshay Munjal; Vikash Kumar; Ankita Behl; Mohammad Abid; Swati Garg; Sonal Gupta; Shailja Singh
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

7.  Catestatin, an endogenous chromogranin A-derived peptide, inhibits in vitro growth of Plasmodium falciparum.

Authors:  Aziza Akaddar; Cécile Doderer-Lang; Melissa R Marzahn; François Delalande; Marc Mousli; Karen Helle; Alain Van Dorsselaer; Dominique Aunis; Ben M Dunn; Marie-Hélène Metz-Boutigue; Ermanno Candolfi
Journal:  Cell Mol Life Sci       Date:  2009-12-31       Impact factor: 9.261

8.  Assessing functional annotation transfers with inter-species conserved coexpression: application to Plasmodium falciparum.

Authors:  Laurent Bréhélin; Isabelle Florent; Olivier Gascuel; Eric Maréchal
Journal:  BMC Genomics       Date:  2010-01-15       Impact factor: 3.969

9.  Cellular effects of curcumin on Plasmodium falciparum include disruption of microtubules.

Authors:  Rimi Chakrabarti; Parkash S Rawat; Brian M Cooke; Ross L Coppel; Swati Patankar
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

10.  A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections.

Authors:  Timothy McEwan; Philip C Robinson
Journal:  Semin Arthritis Rheum       Date:  2020-12-17       Impact factor: 5.532

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.